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ess under CC BY-NC-Abstract Water-insoluble materials containing amorphous solid dispersions (ASD) are an emerging
category of drug carriers which can effectively improve dissolution kinetics and kinetic solubility of poorly
soluble drugs. ASDs based on water-insoluble crosslinked hydrogels have unique features in contrast to
those based on conventional water-soluble and water-insoluble carriers. For example, solid molecular
dispersions of poorly soluble drugs in poly(2-hydroxyethyl methacrylate) (PHEMA) can maintain a high
level of supersaturation over a prolonged period of time via a feedback-controlled diffusion mechanism thus
avoiding the initial surge of supersaturation followed by a sharp decline in drug concentration typically
encountered with ASDs based on water-soluble polymers. The creation of both immediate- and controlled-
release ASD dosage forms is also achievable with the PHEMA based hydrogels. So far, ASD systems based
on glassy PHEMA have been shown to be very effective in retarding precipitation of amorphous drugs in
the solid state to achieve a robust physical stability. This review summarizes recent research efforts in
investigating the potential of developing crosslinked PHEMA hydrogels as a promising alternative to
conventional water-soluble ASD carriers, and a related ﬁnding that the rate of supersaturation generation
does affect the kinetic solubility proﬁles implications to hydrogel based ASDs.
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Crosslinked hydrogels for enhancing the delivery of poorly soluble drugs 271. Introduction
Many new discovery candidates show promising biological
activities, but their low oral bioavailability due to poor aqueous
solubility has become a major challenge in solid oral dosage form
development. There has been signiﬁcant ongoing research in
improving the aqueous solubility of such poorly water-soluble
drug candidates, particularly those small molecular weight
(MWo1000 Da) Biopharmaceutics Classiﬁcation System (BSC)
II (high permeability, low solubility) compounds1. Previous
attempts to address this issue employing solubility enhancing
approaches through chemical (e.g., pro-drug, salt formation) or
physical means (e.g., particle size reduction, complexation/solubi-
lization with cosolvents or surfactants, employing more soluble
polymorphs) have not always been successful in accomplishing the
desired enhancement in solubility and bioavailability2,3. In con-
trast, the formation of stabilized amorphous solid dispersions
(ASD) in an inert carrier has been shown to be very effective in
improving the solubility and bioavailability of poorly water-
soluble drugs due to the generation of a transient but highly
supersaturated solution concentration (or kinetic solubility) from
the ASD, signiﬁcantly greater than the equilibrium solubility of the
crystalline counterpart thus increasing the driving force for its oral
absorption. Earlier investigations of incorporating poorly water-
soluble drugs in solubilizing agents were mostly on identifying
rapidly dissolving small MW carriers (e.g., sulfathiazole–urea4)
and water-soluble polymer carriers (e.g., sulfathiazole-
polyvinylpyrrolidone (PVP)5) to improve the drug dissolution
rate, the degree of supersaturation, and the oral bioavailability.
More recent studies have investigated relevant physicochemical
properties of drug-carrier composites that can enhance the stabi-
lization of metastable amorphous drugs in polymeric carriers
through their ability to inhibit nucleation and crystal growth in
the solid state6–8.
Nevertheless, during dissolution in an aqueous medium, the
kinetic solubility proﬁles of ASDs based on water-soluble poly-
mers generally exhibit an initial surge of drug concentration due to
the rapid buildup of supersaturation followed by a sharp decline in
drug concentration due to the nucleation and crystallization events
triggered by the supersaturation buildup under nonsink dissolution
conditions as commonly encountered under ﬁnite-volume dissolu-
tion conditions in the gastrointestinal (GI) tract. Such a decline inFigure 1 Classiﬁcation of solid dispersion/solutidrug concentration may be retarded to different degrees depending
on the ability of the dissolved polymer to inhibit drug precipita-
tion. Moreover, many such rapidly-dissolving hydrophilic poly-
meric carriers may develop product stability issues due to their
hygroscopic nature3. As a result, there has been growing recent
interest in exploring the preparation of ASDs in a new category of
water-insoluble carriers to enhance stability in the solid state
during storage and mitigate the rapid nucleation and crystallization
during dissolution thereby producing enhanced kinetic solubility
proﬁles. While previous efforts in applying water-insoluble poly-
mers as drug carriers primarily aimed to achieve controlled
release9,10, our group has recently demonstrated the feasibility of
employing the biocompatible crosslinked (i.e., water-insoluble)
poly(2-hydroxyethyl methacrylate) (PHEMA) hydrogel system as
a promising ASD carrier for immediate-release applications11,12.
PHEMA has been widely utilized in controlled release drug
delivery systems particularly for water-soluble drugs and in
biomedical applications such as contact lenses and tissue engineer-
ing. Understandably, properties of the polymer matrix play a key
role in the dissolution behavior of such drug-carrier composites
containing dissolved or dispersed amorphous drugs. The objective
of the present review paper is to examine recent research progress
in developing crosslinked hydrogels as a new class of effective
ASD carriers for poorly water-soluble drugs and to provide an
overview of the unique supersaturation kinetics of hydrogel-based
ASD systems. To contrast the advantages of using crosslinked
hydrogels, a brief survey of known insoluble carriers for amor-
phous drugs will be ﬁrst provided.2. Insoluble carriers for amorphous pharmaceuticals
Physical instability, such as crystallization on ageing, and manu-
facturing challenges have limited the success in commercial
applications of amorphous pharmaceuticals. Since reduced mole-
cular mobility is crucial for the retardation of drug nucleation and
crystallization, the selection of suitable carriers is determined by
the conﬁnement properties of amorphous drugs. Entrapped drug
molecules in polymeric carrier matrices can be classiﬁed as
crystalline solid dispersion (2-phase system), amorphous solid
dispersion (2-phase system) and solid solution (1-phase system) as
illustrated in Fig. 1. Compared to the 1-phase solid solution inon of drug molecules in polymeric carrier matrix.
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the carrier, the 2-phase dispersion systems contain a separated
phase of either crystalline (long-range molecular order) or amor-
phous drugs (short-range molecular order). In reality, formulations
based on ASD may also contain a mixture or hybrid of both the
2-phase and 1-phase systems. In the case of nonporous ASD
carriers where amorphous drug molecules are completely dis-
solved (i.e., one-phase solid solution), carriers with extremely low
drug diffusivities such as “glassy polymers” (i.e., glass transition
temperature, Tg, much higher than the ambient temperature) will
exhibit better ASD stability due to hindered drug diffusion and
inhibition of drug precipitation in the glassy matrix. The presence
of speciﬁc drug-carrier intermolecular interactions due to hydrogen
bonding, dipole-dipole attraction and van der Waals forces further
stabilizes the entrapped amorphous drug preventing it from
nucleating and becoming crystalline. On the other hand, in porous
carriers where the incorporated bulk amorphous drug is localized
in interstitial pore space (i.e., not molecularly dispersed), the
nucleation and crystallization of this bulk amorphous drug can
give rise to stability issues. However, the drug nucleation and
crystallization rates can be reduced if the size of the pore is
sufﬁciently small compared to that of the critical nucleus such
that it is energetically unfavorable for nuclei to grow13–15.
Table 1 summarizes available water-insoluble carriers utilized to
convert poorly water-soluble model drugs into amorphous for-
mulations categorized by their physicochemical characteristicsTable 1 Selected examples of insoluble carriers for amorphous drug
Category Example
Carriera Model Drug
I. Non-porous
a. Crosslinked
hydrogel
cr-PHEMA hydrogel Diclofenac sodium,
naproxen, piroxica
indomethacin
cr-PEO hydrogel Progesterone
Carbopols Phenacetin
b. Water-insoluble
polymer
Ethylcellulose Indomethacin
Eudragits RS, RL Indomethacin,
dipyridamole
c. Lipid Labrasol and
Gelucire 44/14
Piroxicam
Gelucire 44/14
and Gelucire 50/13
Gilbenclamide
II. Porous “Popcorn” cr-PVP Griseofulvin, indome
Silica Fenoﬁbrate, carbama
cinnarizine, danazo
ibuprofen diazepam
griseofulvin, ind
ketoconazole, nifed
phenylbutazone
Starch foam Lovastatin
Carbon Celecoxib
aCarrier: cr-PHEMA, poly(2-hydroxyethyl methacrylate) crosslinked wit
940), polyacrylic acid (lightly crosslinked with allyl sucrose or allyl pentaer
diisocyanate (HMDIC) or tolylene-2,4-diisocyanate (TDIC); cr-PVP, cross
glycol glycerides; Labrasol, caprylocaproyl macrogolglycerides.
bPreparation method: S/SE, swelling/solvent evaporation; C/SE, cosolve
melt; MH, mixing and heating (oTm); SD, spray-drying.
cRelease mode: IR, immediate release; CR, controlled release.such as porosity, location of amorphous drug and carrier chemical
composition.
For inorganic mesoporous materials such as silica and silicon16,
their large surface area and pore volume can accommodate a larger
amount of drug payload. Drug nucleation and crystal growth in the
porous channels will be energetically unfavorable if the size of the
critical nucleus is larger than that of the pore17,18. In other words,
the spatial constraint of a capillary imposed on the amorphous
drug below the critical nucleus size provides the stabilizing effect.
In addition, a strong interaction with the pore walls (e.g., through
hydrogen bonding) further stabilizes the conﬁned drug molecules
in an amorphous state and this typically occurs in nano-sized pores
with pore diameter smaller than approximately 10 nm15. The drug
loading process in such mesoporous materials commonly involves
immersing the carriers in a concentrated drug solution to ﬁll the
pores by capillary action followed by the evaporative removal of
solvent. One study claims to have successfully accomplished solid
dispersion by means of a melt-mixing method, during which a
physical mixture of nitrendipine and mesoporous silica particles is
heated above the melting point of the drug18. Nonetheless, in this
case the high viscosity of the melted drug can interfere with the
capillary action within the pores, potentially causing an incomplete
drug loading. Similar constraints also apply to macroporous poly-
meric carriers such as crosslinked polyvinylpyrrolidone (crospovi-
done) which exhibits a “popcorn” structure, containing many micron-
sized porous cavities, as clearly shown under the SEM19–21.s.
Preparation methodb Release modec Ref.
m,
S/SE IR/CR 11,12
S/SE CR 25
S/SE CR 26
C/SE CR 27
C/SE CR 28,29
HM IR 30
C/SE IR 31
thacin I/SE, MH IR 19–21
zepine,
l,
,
omethacin,
ipine,
I/SE, SD IR 13,14,32
I/SE IR 33
I/SE IR 34
h ethylene glycol dimethacrylate; Carbopols (910, 971P, 934P, 974P,
ythritol); cr-PEO, poly(ethylene oxide) crosslinked with hexamethylene
linked polyvinylpyrrolidone; Gelucire 44/14 and 50/13, polyethylene
nt/solvent evaporation; I/SE, immersion/solvent evaporation; HM, hot
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sorption from a concentrated drug solution, an alternative method of
drug loading based on blending or milling of the drug and porous
crospovidone particles in the absence of solvent under high
mechanical shear for an extended period of time has been
proposed19,20. However, the resulting “amorphous” material could
be a result of the well-known shear-induced phase transformation at
the shear fractured surfaces on drug crystals22,23. As such, the long-
term stability of such mechanically generated amorphous systems is
questionable because, without any mechanism for crystallization
inhibition, this exposed surface amorphous content can easily be
converted to the crystalline phase under accelerated temperature and/
or humidity conditions.
Alternatively, in nonporous insoluble carrier systems, amor-
phous drugs can exist as surface adsorbed or molecularly
dissolved/dispersed in the matrix depending on the drug loading
process. For example, solvent or melt granulation of a poorly
soluble drug with a nonporous insoluble carrier typically results in
bulk amorphous drug either adsorbed on the carrier surface or
unevenly distributed throughout the carrier-drug granule (i.e., a
two-phase amorphous solid dispersion). Such surface adsorbed or
unevenly distributed bulk amorphous drug lacks the beneﬁt of
crystallization inhibition conferred by dissolving or molecularly
dispersing the drug in a protective carrier matrix and, therefore, is
prone to undesirable nucleation and crystallization events in the
solid state. On the other hand, the creation of uniformly dissolved
or molecularly dispersed drug in ASD polymeric carriers (i.e., one-
phase solid solution) through either drug sorption (e.g., from a
good swelling solvent) or coprecipitating from a common organic
solvent (e.g., via spray drying or freeze drying) is understandably
more advantageous than producing dispersed two-phase ASD
systems due to its effectiveness in crystallization inhibition and
its effect in enhancing the physical stability. For this purpose,
applicable nonporous water-insoluble carriers include crosslinked
polymers (e.g., PHEMA), cellulose derivatives (e.g., ethylcellu-
lose), and lipids (e.g., PEG-glycerides). The common methods of
preparation of ASD based on water-insoluble carriers can be
generally classiﬁed as supercooling of the melt (e.g., hot-stage
melting, hot-melt extrusion), coprecipitating from a common
organic solvent (e.g., spray-drying, freeze-drying), and equilibrium
sorption (e.g., from a concentrated drug solution prepared in a
good swelling solvent) to produce a homogenous binary one-phase
system. In this case, the carrier plays an essential role in preserving
the entrapped drug molecules in the amorphous state despite the
fact that the exact mechanisms of crystallization inhibition in solid
molecular dispersions are still not completely understood. Various
factors such as molecular mobility, thermodynamic factors, and
drug-polymer interactions have been identiﬁed as being respon-
sible for inhibiting drug crystallization from the amorphous
state7,8,24. Stressed stability conditions involving high relative
humidity, high temperature in combination with ageing may
accelerate the transformation of metastable amorphous drug in
an ASD into more thermodynamically stable crystalline state6,24.3. Amorphous solid dispersions in crosslinked hydrogels
In selecting an appropriate polymer matrix for an ASD system, the
carrier polymer must provide sufﬁcient stabilization effect in the
solid state to prevent the entrapped amorphous drug from crystal-
lizing, thereby achieving a reasonable shelf life. From a mechan-
istic point of view, nucleation and subsequent crystallization of anamorphous drug in a polymer matrix deplete the local drug
concentration around the crystallite and thus triggering drug
diffusion from the surrounding amorphous drug region to the
crystallite surface to sustain crystal growth. The reduced segmental
mobility of polymer chains in glassy PHEMA hydrogels at
ambient temperature well below its Tg of 115 1C
35 lengthens the
polymer molecular relaxation time and retards the diffusional
mobility as well as the nucleation and crystallization rates of the
entrapped molecularly dispersed drug, thus resulting in enhanced
stability of such hydrogel-based solid dispersion systems. An
added advantage is that PHEMA hydrogels exist as optically clear
glassy solids at ambient temperature, which is suitable for direct
microscopic examination for any phase transformation and for the
determination of the drug loading threshold in the hydrogel matrix
above which amorphous-to-crystalline transition may occur.
In addition to the physical stability of ASDs, the extent of
solubility and dissolution enhancement is another key criterion to
consider in selecting an appropriate ASD carrier. Typically, kinetic
solubility proﬁles of ASDs based on conventional water-soluble
polymers under nonsink dissolution conditions show an instanta-
neous dissolution causing an initial surge of drug concentration
followed by a sharp decline owing to the nucleation and crystal-
lization events triggered by the rapid buildup of drug super-
saturation. On the other hand, ASDs based on water-insoluble
hydrogels exhibit a unique sustained supersaturation without the
initial rapid buildup of supersaturation as will be described in more
detail below. For a long while, the kinetics of drug release from
crosslinked water-insoluble hydrogels was characterized only in
the context of achieving controlled drug release under perfect sink
dissolution conditions36, and the application of crosslinked hydro-
gels as carriers for ASDs was never explored and effect of the
hydrogel matrix on the maintenance of supersaturation was
virtually unknown. To bridge this gap, our group for the ﬁrst
time employed crosslinked PHEMA hydrogel beads as ASD
carriers to enhance the solubility and dissolution rate of poorly
soluble drugs suitable for immediate-release oral drug delivery and
to investigate the extent of enhancement of kinetic solubility
proﬁles and supersaturation maintenance under nonsink dissolu-
tion conditions12. It was observed that the diffusion-controlled
kinetics of drug release from crosslinked PHEMA hydrogels
provides a feedback-controlled mechanism to prevent a rapid
buildup of supersaturation in the dissolution medium thus avoiding
the undesirable nucleation and crystallization events leading to a
sharp decrease in drug concentration. This unique diffusion-
controlled feedback mechanism regulates the dissolution of
entrapped amorphous drugs from the hydrogel matrix to maintain
an elevated level of supersaturation for an extended period of time
even without the presence of any dissolved polymer or crystal-
lization inhibitor. This aspect and its implications will be discussed
in more detail in the following sections.3.1. Preparation and physicochemical characterization
Based on previously reported protocols37, spherical PHEMA hydrogel
beads can be synthesized by a free radical initiated suspension
polymerization process. Afterwards, the PHEMA hydrogel beads can
be extracted in a Soxhlet with a mixture of water, methanol and
ethanol, dried under vacuum before being fractionated and stored in
desiccators until use. Although PHEMA is probably the most widely
studied gel-forming crosslinked polymer, several other synthetic
hydrogels based on nonionic hydrophilic monomers (e.g., hydroxyalkyl
D.D. Sun, P.I. Lee30acrylate, N-substituted methacrylamides and N-vinyl-2-pyrrolidone) are
also commonly used in swelling-controlled oral drug delivery38. The
drug release kinetics and release rate modulation from such a spherical
monolithic diffusion-controlled system have previously been character-
ized in detail39–41. Chemically, PHEMA has hydrophilic side groups
that can promote the sorption of a signiﬁcantly large amount of polar
solvent, thereby providing desired conditions to create solid dispersions
with high drug loading. PHEMA can also be easily copolymerized
with other hydrophobic monomers, such as methyl methacrylate
(MMA) or its homologs, to improve the compatibility of the hydrogel
matrix with hydrophobic drugs. Furthermore, the crosslinker chain
length and crosslining density can be adjusted to affect the network
mesh size which provides further control of the diffusional drug
release59. Thus, PHEMA is a good candidate drug carrier because of
the ease in regulating drug release by controlling particle size,
crosslinking density, chemical composition (e.g., copolymers) and
water sorption rate to achieve different drug loading levels and release
proﬁles suitable for oral drug delivery.
ASD in PHEMA hydrogels with various levels of drug loading
can be achieved by equilibrating puriﬁed PHEMA beads in a
concentrated drug solution prepared in a good swelling solvent
(e.g., ethanol). Subsequent ﬁltration, rinsing and vacuum drying
after the equilibrium sorption process result in glassy hydrogel
beads containing uniformly dissolved or dispersed drug. This
preparation method involving swelling, drug sorption, followed by
solvent evaporation requires the evaporative removal of only a
limited amount of solvent imbibed into the hydrogels during the
drug loading process, thereby signiﬁcantly reducing the amount of
organic solvent usage comparing to that of the conventional spray
drying process for ASDs based on water-soluble polymers where
the removal of 90% w/w or more organic solvent is typically
required. Thus far, ASDs of model poorly water-soluble drugs
such as diclofenac sodium, naproxen, piroxicam and indomethacin
have been successfully incorporated in PHEMA hydrogels with a
maximum drug loading up to approximately 40–50% w/w11,12.
For example, indomethacin-loaded PHEMA hydrogel beads at
various drug loading levels as a function of crosslinking agent
concentration and loading solution concentration are shown in
Fig. 2, where a transition of physical appearance from being pale
yellow and transparent (i.e., containing dissolved drug) to opaque
(i.e., containing precipitated drug) when the drug loading exceeds
a threshold of approximately 40% w/w indomethacin. Representa-
tive surface and cross-sectional SEM images of Fig. 3 illustrate
that both pure PHEMA and indomethacin-loaded PHEMA hydro-
gel beads appear to be homogenous and nonporous in morphology
in the interior without any signiﬁcant surface irregularities. The
physical state (e.g., amorphous or crystalline polymorph) of the
loaded drug can be conﬁrmed by the presence of certain
characteristic peaks in the X-ray diffraction (XRD) patterns of
the drug-loaded hydrogel beads. A threshold drug loading level of
up to 30%–40% w/w typically exists in PHEMA hydrogels above
which amorphous-to-crystalline transition tends to occur11,12. No
drug melting endotherms were detected from the differential
scanning calorimetry (DSC) thermograms of drug-PHEMA ASD
samples below such threshold drug loading level, reﬂecting the
existence of a completely amorphous phase of dissolved drug in
the hydrogel matrix. The thermal analysis by DSC also shows that
the Tg of drug-PHEMA ASD decreases as the drug loading
increases due to the plasticizing effect of dissolved drug on the
polymer network (i.e., PHEMA has a Tg much higher than that of
the model drugs). In addition, spectroscopic analysis by fourier
transformed inferred (FTIR) was used to conﬁrm the presence ofhydrogen bonding between the drug and the polymer in diclofenac
sodium-, naproxen- and indomethacin-PHEMA ASD samples. A
robust physical stability has also been demonstrated in
indomethacin-PHEMA ASD by using polarized light microscopy
to detect the onset of drug precipitation and no drug precipitation was
observed for up to 8 months under direct exposure to an accelerated
storage condition (40 1C/75% RH) for indomethacin loading levels
below 16.7% w/w12.
3.2. Swelling kinetics
The swelling property of crosslinked hydrogels is important not
only to reach an adequate drug loading but also to regulate the rate
of drug release. During drug release, the time evolution of the
solvent penetrating front and normalized dimensional changes of
drug-loaded PHEMA hydrogel beads is a function of crosslinking
density, drug solubility and initial drug loading. For example, two
moving boundaries (swelling front and drug dissolution front)
were generally observed for poorly water-soluble diclofenac
sodium in PHEMA hydrogels at a high drug loading range of
25%–30% w/w as the aqueous medium penetrates into the matrix,
whereas a single fast-moving swelling front was observed below
this range of drug loading40. The dimensional changes of swelling
PHEMA beads generally go through a maximum in radius
followed by a gradual decrease to an equilibrium dimension
during the drug release37,40. Therefore, in PHEMA-based ASD
systems, as the swelling phase progresses, the amorphous drug
entrapped in the PHEMA hydrogel will be ﬁrst converted into
supersaturated solution and then released by diffusion into the
dissolution medium. Meanwhile, the unreleased drug in the
swollen matrix is still conﬁned in the interstitial space between
crosslinked polymer chains which can interact with the PHEMA
polymeric network thereby inhibiting its rapid nucleation and
crystallization in the hydrogel phase until the dissolved drug is
released into the external medium in a more diluted form. The
swelling behavior of hydrogels and the inhibition of drug nuclea-
tion and crystallization in the swollen gel phase are unique
characteristics that are absent in conventional water-soluble and
porous water-insoluble ASD carrier systems.
3.3. Diffusional drug release kinetics
The dissolution of ASD from insoluble crosslinked PHEMA
hydrogels is regulated by a diffusion-controlled mechanism where
the hydrogel matrix is insoluble and the dissolved amorphous
drug (converting into highly supersaturated drug solution) slowly
diffuses out of the hydrogel network. As a result, the degree of
supersaturation in the dissolution medium generated by the
PHEMA ASD system gradually increases. This gradual accumula-
tion of drug concentration in the external medium reduces the
driving force (i.e., drug concentration difference between the
hydrogel and the external medium) thus slowing the drug release
from the hydrogel matrix. This feedback-controlled mechanism
allows the avoidance of the critical supersaturation window above
which spontaneous nucleation and crystallization will occur.
As discussed in Section 3.2, entrapping the supersaturated drug
solution in the swollen hydrogel phase can inhibit the nucleation
and crystallization rates until the drug is released by diffusion from
the hydrogel surface into the external medium in a more diluted
form. On the other hand, ASDs based on water-soluble polymer
carriers are generally dissolved quickly in the early stage of the
Figure 2 Characteristics of indomethacin-loaded PHEMA beads as a function of crosslinking agent concentration and loading solution
concentration. Photographs of corresponding indomethacin-PHEMA samples on scale lines of a microscope slide (between scale lines: 100 μm)
showing evidence of the threshold of drug loading levels. Figure adapted from reference 12 (reproduced with permission from the European
Journal of Pharmaceutics and Biopharmaceutics, Copyright Elsevier 2012).
Figure 3 SEM images showing surface morphology (A–C) and cross section (D–F) of PHEMA beads (crosslinked with 0.66 mol% EDGMA) at
different indomethacin loading levels: (A) 48.1% w/w, (B) 26.1% w/w, (C) 0% w/w, (D) 41.4% w/w, (E) 26.1% w/w and (F) 0% w/w. Images
adapted from reference 12 (reproduced with permission from the European Journal of Pharmaceutics and Biopharmaceutics, Copyright
Elsevier 2012).
Crosslinked hydrogels for enhancing the delivery of poorly soluble drugs 31dissolution process resulting in an initial surge of supersaturation
followed by a decline in drug concentration due to the nucleation
and crystallization events originated from the rapid buildup of
supersaturation. However, such a decline in drug supersaturation
can be delayed to different extents depending on the stabilizing
effects of the dissolved polymer in the dissolution medium.
Among various available water-soluble polymer carriers, hydro-
xypropyl methylcellulose acetate succinate (HPMCAS) has been
identiﬁed as the most effective in achieving and maintaining drugsupersaturation when employed in ASDs42,43. To provide a head-
to-head comparison of solubility enhancement, the kinetic solubi-
lity proﬁles of indomethacin ASD in PHEMA, PVP (another
commonly used hydrophilic polymer for ASD) and HPMCAS
under nonsink dissolution conditions are presented in Fig. 4.
A sink index (SI) deﬁned as SI¼CsV/(Dose) is used here to
characterize the extent of deviation from sink condition for the
dissolution experiments of supersaturated ASD samples, where Cs
is the solubility of crystalline drug, V the volume of dissolution
Figure 4 Comparison of IND dissolution proﬁles from ASD versus that of crystalline IND under nonsink dissolution condition (SI¼0.1): (A)
ASD with 10.0% w/w IND in PHEMA (average particle size 108 μm), PVP (63 μm) and HPMCAS (63 μm) and (B) ASD with 32.9% w/w IND in
PHEMA (108 μm), PVP (63 μm), HPMCAS (63 μm). Figure adapted in part from reference 12 (reproduced with permission from the European
Journal of Pharmaceutics and Biopharmaceutics, Copyright Elsevier 2012).
Figure 5 Amorphous drug release mechanism: crosslinked hydro-
gels vs. water-soluble polymers.
D.D. Sun, P.I. Lee32medium, and Dose the total amount of drug in the sample12.
A larger SI translates to a dissolution system that is closer to the
sink condition (note: a perfect sink condition is achieved when
SI410). It can be seen that the initial indomethacin solubility
enhancement is higher for ASDs based on PVP and HPMCAS but
the extent of solubility enhancement of indomethacin ASD in
PHEMA falls between those in PVP and HPMCAS at 10.0% w/w
drug loading after 6 h (Fig. 4A) and outperforms those in PVP and
HPMCAS at 32.9% w/w drug loading after 8 h (Fig. 4B) under
nonsink dissolution conditions (SI¼0.1). It is worth noting that in
this case the dissolution medium for the indomethacin-PHEMA
ASD system remains supersaturated even after 24 h in the absence
of any dissolved polymer which may inhibit crystallization. The
apparent ﬁrst-order drug dissolution from ASD indomethacin in
PHEMA represents a balance of interrelated processes of
diffusion-controlled drug release from the hydrogel matrix and
recrystallization of supersaturated drug solution in the dissolution
medium under nonsink dissolution conditions.
During the dissolution from PHEMA-based ASDs, the initial
buildup of drug concentration in the external dissolution medium
reduces the diffusional driving force for the drug to be further
released from the matrix (i.e., feedback-controlled mechanism),
thus preventing the creation of excessively supersaturated drug
solution in the dissolution medium thereby avoiding the critical
supersaturation window above which spontaneous nucleation and
crystallization will occur. When nuclei and crystallites start to
form and consume dissolved drug molecules from the super-
saturated dissolution medium, any reduction in drug concentration
from such events will promote additional drug release from the
matrix to maintain supersaturation for an extended period of time.
Such coupled feedback-controlled balancing scheme will continue
until no drug can be further released from the hydrogel matrix,
beyond which drug concentration in the supersaturated dissolution
medium will eventually decline due to continued nucleation and
crystallization events. Therefore, ASD in hydrogels exhibits a
completely different overall concentration–time curve than that
based on soluble polymers primarily because the feedback-
controlled diffusion mechanism avoids a sudden surge of super-
saturation in the surrounding dissolution medium and thus
prevents spontaneous and uncontrolled nucleation/crystallization.This enhancement of kinetic solubility proﬁles is evidently shown
by the lack of any depreciation of drug concentration during the
ﬁrst 24 h of dissolution (Fig. 4) which contrasts the concentration
decline normally encountered with ASDs based on water-soluble
Figure 6 Comparison of kinetic solubility proﬁles of indomethacin
between experimental and predicted results as a function of supersaturation
rate generated with various drug solution (indomethacin in ethanol)
infusion rates under nonsink dissolution condition (SI¼0.1). Figure
adapted in part from reference 47 (reproduced with permission from
Molecular Pharmaceutics, Copyright American Chemical Society 2013).
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lary here is that other properly designed diffusion-controlled
matrix ASD systems in principle should exhibit advantageous
kinetic solubility proﬁles and maintenance of supersaturation
similar to that of the present hydrogel ASD system. The strategy
of employing diffusion-controlled drug release (whether short or
extended term) will therefore provide the necessary feedback
control to maintain supersaturation and avoid rapid nucleation
and crystallization events in the dissolution medium under nonsink
dissolution conditions.
To further illustrate the above described differences in drug
release mechanism, Fig. 5 depicts the evolution of supersaturation
of amorphous drugs released from crosslinked hydrogels versus
that from water-soluble polymers. When used as immediate-
release dosage forms, ASD based on water-soluble polymers tends
to produce a highly supersaturated local environment upon
dissolution of the polymer carrier, which often results in rapid
recrystallization of the dissolved drug, thereby reducing the local
drug concentration and the achievable supersaturation level of the
solid dispersions. It is therefore not surprising that solid disper-
sions of poorly water-soluble drugs in water-soluble polymers
usually experience rapid drug recrystallization from supersaturated
drug solution upon dissolution of the water-soluble polymer
carriers. Whereas the ASD in hydrogels avoids a sudden surge
of supersaturation in the surrounding dissolution medium through
the above described feedback-controlled diffusion mechanism and
thus achieving a more sustained level of supersaturation than that
based on water-soluble polymers. This further demonstrates the
potential comparative advantage of designing an oral ASD dosage
form based on crosslinked hydrogels.3.4. Effect of rate of supersaturation generation
As discussed above, a sustained level of supersaturation can be
achieved by gradual drug dissolution from ASD based on cross-
linked PHEMA hydrogels, later surpassing that based on water-
soluble polymer carriers as the drug concentration in the latter case
declines due to more rapid de-supersaturation12. Similar observa-
tions showing more sustained supersaturation resulting from a
more gradual drug release under nonsink dissolution conditions
have also been reported for drug release from swelling clay
minerals44 and ordered mesoporous silica materials14 in the
absence of any crystallization inhibitor. In addition, Six et al.45
have demonstrated that Sporanoxs, an ASD formulation of
itraconazole in polymeric carrier HPMC having a slower in vitro
dissolution rate than ASD prepared in Eudragit E100 and Eudragit
E100/PVPVA64, actually produces a better oral bioavailability
enhancement for itraconazole. In fact, fast dissolution of a super-
saturating drug delivery system does not always translate to an
optimal in vivo performance14,46. These observations suggest that
the rate of supersaturation generation may play an important role
in determining the overall kinetic solubility proﬁles and the level
of supersaturation achieved. Although the degree of supersatura-
tion is well recognized as the driving force for the nucleation and
crystallization processes, the effect of rate of supersaturation
generation on the time evolution of the overall kinetic solubility
proﬁles was not recognized and had not been explored prior to our
work. We have recently shown for the ﬁrst time that the rate of
supersaturation generation plays an important role in determining
the level of transient solubility enhancement, thereby affecting the
overall kinetic solubility proﬁles in a dissolution medium free ofany crystallization inhibition47. We also proposed a comprehen-
sive mechanistic model based on the classical nucleation theory
taking into account both the particle growth and ripening processes
to predict experimental kinetic solubility proﬁles under varying
rates of supersaturation generation and recrystallization. This semi-
quantitative analysis elucidates the dependency of the overall time-
concentration proﬁles on the rate of supersaturation generation
from the dissolution of non-equilibrium amorphous drugs. In the
absence of any dissolved polymer or crystallization inhibitor, both
of the experimental data and predicted results conﬁrm that the
faster rise of supersaturation will inevitably lead to an earlier but
higher maximum kinetic solubility and a sharper decline in the de-
supersaturation phase. Conversely, a slower rate of supersaturation
generation results in a lower maximum kinetic solubility followed
by a more gradual decline in drug concentration. These trends are
clearly illustrated in Fig. 6 where experimental data at different
rates of supersaturation generation (through drug infusion) are
compared with simulated results based on our comprehensive
mechanistic model47. Given the fact that the mechanistic model
simulation was based solely on physical parameters reported in the
literature without employing any curve ﬁtting, the agreement
between the experimental data and model prediction can be
considered as quite good. These trends are also consistent with
our results on ASDs based on crosslinked PHEMA hydrogels as
reported in Figs. 4 and 5 where a slower drug release from the
hydrogel results in a lower but broader and more sustained drug
supersaturation.4. Safety assessment of hydrogel system for oral dosage form
Orally administered excipients must be stable, non-toxic, biocom-
patible in the GI tract and compatible to API and other excipients
in the formulation in order to satisfy regulatory requirements. Full
in vivo studies such as biodistribution, immune response, clearance
and chronic toxicology studies for different durations are generally
needed to demonstrate that new excipient is safe for usage in
human drug products. The approval process of introducing a novel
pharmaceutical excipient onto the market requires expensive
D.D. Sun, P.I. Lee34toxicological investigations and typically takes a similar period of
time as that of a new API48. Due to the complexity and high cost
of long-term toxicological and clinical testing, PHEMA has not yet
been used as an oral excipient in FDA approved drug products49.
Nevertheless, PHEMA hydrogel has a long history of human use
as biomedical implants and for controlled drug release from
medical devices such as contact lenses and wound dressings. A
number of in vivo tests using PHEMA hydrogel delivery systems
have produced favorable results in blood and tissue compatibil-
ity50–53. Moreover, no toxic abnormalities were reported when
crosslinked PHEMA hydrogels loaded with diclofenac sodium and
theophylline were administered orally and rectally, respectively, to
human subjects in clinical PK studies54,55. Since crosslinked
hydrogels for the oral delivery purpose are generally of micron
sizes and insoluble in the GI ﬂuid, cellular internalization or
absorption through the mucosal membrane of the GI tract is very
unlikely. Therefore, the above mentioned lines of evidence suggest
that crosslinked PHEMA hydrogel beads would be an attractive
candidate excipient for oral ASD drug products to enhance the
solubility and bioavailability of poorly water-soluble drugs. To
promote the practical application of PHEMA hydrogels as an
excipient for oral ASD dosage forms, long-term oral toxicity
studies should be investigated and safety established in the future.5. Rate-controlled drug release from PHEMA Hydrogel
Controlled-release (CR) formulations have several potential advan-
tages over immediate-release (IR) dosage forms, such as providing
a more uniform and prolonged therapeutic effect to improve
patient compliance, reducing the frequency of dosing, minimizing
the number of side effects and reducing the strength of the required
dose while increasing the effectiveness of the drug. CR-ASD
formulations of poorly water-soluble drugs should comprise both
functions of solubility enhancement and modulation of the rate of
drug release. Unfortunately, complicated design of CR-ASD
formulations often leads to poor reproducibility of physicochem-
ical properties, difﬁculties in dosage form development, less
feasible for scale-up manufacturing, and potential physical
instability9. On the other hand, PHEMA hydrogel beads can easily
achieve sustained release by adjusting appropriate particle size and
chemical composition (e.g., copolymerizing with hydrophobic
monomers). Different from other complicated designs of CR-
ASD formulations such as an osmotic pump system, PHEMA
provides versatility of designing either IR or CR delivery systems
for amorphous pharmaceuticals using the same hydrogel matrix. In
addition to adjusting the drug release proﬁles of PHEMA hydro-
gels through co-polymerization with other monomers to affect the
macromolecular relaxation process during the swelling phase56,59,
modulation of drug release from PHEMA hydrogels is also
feasible by generating a non-uniform initial drug concentration
distribution in the hydrogel matrix to accomplish a near constant-
rate drug release57,58.6. Conclusions
Contrary to optimistic expectations from a large number of relevant
previous studies, only a handful of marketed oral drug products
have been derived from amorphous pharmaceuticals, in spite of a
long history of research and publications since the early 1960s.
At present, for instance, only Gris-PEGs (griseofulvin-PEG,antifungal, Dorsey/Sandoz), Sporanoxs capsules (itraconazole-
HPMC, antifungal, Jessen Pharmaceutica), Cesamets (nabilone-
PVP, pain relief, Eli Lilly) and Kaletras tables (lopinavir/ritonavir
in PVP-VA, Abbvie) are commercially available as immediate-
release solid dispersion systems. Practically no controlled release
oral products based on pharmaceutical solid dispersions have been
commercially developed although many poorly water-soluble drugs
would require additional release-rate modulation to enhance the
duration and/or onset of action while minimizing drawbacks due to
their short half-lives, gastric irritation potential or slow onset of
action. Solid dispersion systems in PHEMA hydrogels would be
ideal for achieving immediate release of amorphous drugs as well as
a modulated release through appropriate selection of polymer
composition and particle size for release rate control. Such hydrogel
based ASDs are attractive because they can avoid a sudden surge of
supersaturation during dissolution through a feedback-controlled
diffusion mechanism and thus achieving a more sustained level of
supersaturation than that based on conventional water-soluble
polymers. This approach should bring hope for designing more
versatile and more cost-effective oral dosage forms for potential
drug candidates that have low aqueous solubility without resorting
to the more complicated dosage design such as push-pull types of
multi-layer osmotic pumps in tablet or capsule form. While the
in vitro dissolution results of ASD based on PHEMA hydrogels
show assuring applicability for oral drug delivery as a platform for
both immediate- and controlled-release delivery of poorly water-
soluble drugs, whether such solubility advantage can translate into
in vivo bioavailability enhancement requires further conﬁrmation.
The current comparative research on solid molecular dispersions
of amorphous pharmaceuticals in PHEMA hydrogels versus other
carrier systems also contributes to the general scientiﬁc under-
standing on factors such as the rate of supersaturation generation,
supersaturation level and crystallization kinetics on the overall
kinetics solubility proﬁles generated by various supersaturating
drug delivery systems.Acknowledgments
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